Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 May 24;131(21):2278-2280.
doi: 10.1182/blood-2018-04-841908.

The future of kinase inhibitors for DLBCL?

Sarah E M Herman  1
Affiliations
Comment

The future of kinase inhibitors for DLBCL?

Sarah E M Herman. Blood. .

Abstract

In this issue of Blood, Battistello et al present results exploring inhibition of signaling across key nodes in the B-cell receptor (BCR) signaling pathway for Bruton tyrosine kinase (BTK)-sensitive and BTK-insensitive diffuse large B-cell lymphoma (DLBCL).

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The author declares no competing financial interests.

Figures

None
BCR signaling in DLBCL cells at baseline or after treatment. BCR signaling in DLBCL at baseline (A) after treatment with ibrutinib in a BTK-sensitive cell (B) or BTK-insensitive cell (D), or after treatment with the pan-SRC inhibitor masitinib (C). Red shading indicates inhibition of protein signaling, and blue shading indicates activation of protein signaling. The extent of shading corresponds with the extent of change. P, phosphorylation sites. Professional illustration by Somersault18:24.
See this image and copyright information in PMC

Comment on

References

    1. Battistello E, Katanayeva N, Dheilly E, et al. Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma. Blood. 2018;131(21):2345-2356. - PMC - PubMed
    1. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194(12):1861-1874. - PMC - PubMed
    1. Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922-926. - PMC - PubMed
    1. Havranek O, Xu J, Köhrer S, et al. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. Blood. 2017;130(8):995-1006. - PMC - PubMed
    1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. - PMC - PubMed

Substances